Balyasny Asset Management
PRME icon

Balyasny Asset Management’s Prime Medicine PRME Stock Holding History

Balyasny Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.3M Buy
4,123,365
+999,003
+32% +$3.8M 0.02% 842
2025
Q4 		$10.8M Buy
3,124,362
+3,076,489
+6,426% +$13.7M 0.01% 983
2025
Q3 		$265K Buy
+47,873
New +$194K ﹤0.01% 2628
2025
Q1 		– Sell
-16,342
Closed -$47.7K – 3189
2024
Q4 		$47.7K Buy
+16,342
New +$57.4K ﹤0.01% 2640
2024
Q3 		– Sell
-12,101
Closed -$62.2K – 3080
2024
Q2 		$62.2K Buy
+12,101
New +$73.4K ﹤0.01% 2429

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Balyasny Asset Management's PRME Position: Q1 2026 in Review

Balyasny Asset Management increased its Prime Medicine (PRME) stake by 32% in Q1 2026, buying an estimated $3.8M and bringing the position to 4,123,365 shares worth $14.3M. The position accounts for 0.02% of the portfolio, ranked #842.

Balyasny Asset Management first reported a position in PRME in Q2 2024 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Balyasny Asset Management held 4,123,365 shares of Prime Medicine worth $14.3M as of Q1 2026.
  • Balyasny Asset Management bought 999,003 Prime Medicine shares in Q1 2026, an estimated $3.8M.
  • Prime Medicine made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #842 holding.
  • Balyasny Asset Management first reported a position in Prime Medicine in Q2 2024 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.